Abstract
Cell models of tauopathy were generated in order to study mechanisms of neurodegeneration involving abnormal changes of tau. They are based on neuroblastoma cell lines (N2a) that inducibly express different forms of the repeat domain of tau (tauRD), e.g. the 4-repeat domain of tau with the wild-type sequence, the repeat domain with the ΔK280 mutation (“pro-aggregation mutant”), or the repeat domain with ΔK280 and two proline point mutations (“anti-aggregation mutant”). The data indicate that the aggregation of tauRD is toxic, and that aggregation and toxicity can be prevented by low molecular weight compounds, notably compounds based on the N-phenylamine core. Thus the cell models are suitable for developing aggregation inhibitor drugs.
Keywords: Alzheimer's disease, paired helical filaments, tau, drug screening
Current Alzheimer Research
Title: N-Phenylamine Derivatives as Aggregation Inhibitors in Cell Models of Tauopathy
Volume: 4 Issue: 4
Author(s): M. Pickhardt, J. Biernat, I. Khlistunova, Y.-P. Wang, Z. Gazova, E.-M. Mandelkow and E. Mandelkow
Affiliation:
Keywords: Alzheimer's disease, paired helical filaments, tau, drug screening
Abstract: Cell models of tauopathy were generated in order to study mechanisms of neurodegeneration involving abnormal changes of tau. They are based on neuroblastoma cell lines (N2a) that inducibly express different forms of the repeat domain of tau (tauRD), e.g. the 4-repeat domain of tau with the wild-type sequence, the repeat domain with the ΔK280 mutation (“pro-aggregation mutant”), or the repeat domain with ΔK280 and two proline point mutations (“anti-aggregation mutant”). The data indicate that the aggregation of tauRD is toxic, and that aggregation and toxicity can be prevented by low molecular weight compounds, notably compounds based on the N-phenylamine core. Thus the cell models are suitable for developing aggregation inhibitor drugs.
Export Options
About this article
Cite this article as:
Pickhardt M., Biernat J., Khlistunova I., Wang Y.-P., Gazova Z., Mandelkow E.-M. and Mandelkow E., N-Phenylamine Derivatives as Aggregation Inhibitors in Cell Models of Tauopathy, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788765
DOI https://dx.doi.org/10.2174/156720507781788765 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
P-Glycoprotein, but not Multidrug Resistance Protein 4, Plays a Role in the Systemic Clearance of Irinotecan and SN-38 in Mice
Drug Metabolism Letters Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design Antibody-Targeted Immunoliposomes for Cancer Treatment
Mini-Reviews in Medicinal Chemistry MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Subcellular Trafficking in Rhabdovirus Infection and Immune Evasion: A Novel Target for Therapeutics
Infectious Disorders - Drug Targets Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Endogenous Regulators of Adult CNS Neurogenesis
Current Pharmaceutical Design Amyloidophilic Compounds for Prion Diseases
Infectious Disorders - Drug Targets Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease
Current Molecular Pharmacology Theranostic Applications of Nanomaterials in Alzheimer’s Disease: A Multifunctional Approach
Current Pharmaceutical Design The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds Mechanisms of Prion Protein Aggregation
Protein & Peptide Letters From the Oxygen to the Organ Protection: Erythropoietin as Protagonist in Internal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry A Functional Scaffold in Marine Alkaloid: An Anticancer Moiety for Human
Current Medicinal Chemistry